BINEX CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 15,000 KRW | +0.67% |
|
+8.62% | +67.60% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
| Sales 2022 | 157B 114M | Sales 2023 | 155B 113M | Capitalization | 277B 202M |
|---|---|---|---|---|---|
| Net income 2022 | 12.44B 9.08M | Net income 2023 | 4.67B 3.41M | EV / Sales 2022 | 2.39 x |
| Net Debt 2022 | 17.95B 13.1M | Net Debt 2023 | 40.05B 29.24M | EV / Sales 2023 | 2.05 x |
| P/E ratio 2022 |
28.7
x | P/E ratio 2023 |
82.6
x | Employees | 570 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 81.29% |
More Fundamentals
* Assessed data
More news
| 1 day | +0.67% | ||
| 1 week | +8.62% | ||
| Current month | +7.07% | ||
| 1 month | +18.86% | ||
| 3 months | +32.51% | ||
| 6 months | +87.73% | ||
| Current year | +67.60% |
1 week
13 530.00
16 260.00
1 month
12 100.0016 260.00
Current year
8 190.0018 480.00
1 year
7 240.0018 480.00
3 years
7 240.0025 900.00
5 years
6 090.0039 400.00
10 years
6 090.0039 400.00
| Managers | Title | Age | Since |
|---|---|---|---|
Hyuk-Jong Lee
CEO | Chief Executive Officer | 54 | - |
Myoung-Ho Jeong
CHM | Chairman | 57 | - |
Myong-Chul Lee
BRD | Director/Board Member | 65 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Hyuk-Jong Lee
CEO | Chief Executive Officer | 54 | - |
Myoung-Ho Jeong
CHM | Chairman | 57 | - |
Myong-Chul Lee
BRD | Director/Board Member | 65 | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-10 | 15,000 | +0.67% | 1,082,901 |
| 24-05-09 | 14,900 | -3.75% | 765,109 |
| 24-05-08 | 15,480 | -3.25% | 1,652,539 |
| 24-05-07 | 16,000 | +19.14% | 4,350,322 |
| 24-05-03 | 13,430 | -2.75% | 613,057 |
End-of-day quote Korea S.E., May 09, 2024
More quotes
BINEX.CO.LTD is a Korea-based company mainly engaged in the manufacturing and distribution of pharmaceuticals. The Companyâs products include digestive system agents, circulatory system agents, ulcer agents, antacids, anti-inflammatory agents, analgesics, gastrointestinal (GI) tract regulators and antispasmodics, antiemetic drugs, antihistamines, laxatives, antihypertensive and urinary agents, antibacterial and antibiotic agents, cough and cold remedies, anti-diabetic medicines, ophthalmic solutions, vitamins, nutrients, as well as ointment, creams and others. It also manufactures bio medicines and raw materials. The Company distributes its products within domestic market and to overseas markets.
Sector
Pharmaceuticals
Calendar
2024-05-13
- Q1 2024 Earnings Release (Projected)
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +67.60% | 337M | |
| +30.38% | 695B | |
| +26.51% | 568B | |
| -4.36% | 361B | |
| +19.30% | 330B | |
| +3.73% | 283B | |
| +16.70% | 239B | |
| +8.78% | 204B | |
| -7.93% | 198B | |
| +7.68% | 168B |
- Stock Market
- Equities
- A053030 Stock